Lung function in adolescents receiving high-dose methotrexate

Michael Wall, M. E B Wohl, N. Jaffe, D. J. Strieder

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Methotrexate (MTX) has been implicated as a cause of interstitial pneumonitis and/or fibrosis, but the mechanism by which the drug causes these processes is not known. The purpose of this study was to determine whether patients receiving high-dose MTX developed a consistent decrease in pulmonary function, which would implicate a role for total dose of MTX received in the pathogenesis of the lung toxicity. Pulmonary function studies, including spirometry, plethysmography, and diffusing capacity at two levels of alveolar P(O)2, were performed in 38 adolescents treated for osteogenic sarcoma. The patients were divided into three groups including 12 patients (group 1) studied before and during therapy, 15 patients (group 2) studied during therapy, and 11 patients (group 3) studied after completion of treatment. While total dose received at the time of the study varied from 0 to 256 gm/sq m, pulmonary function showed no change, with one exception. A mild restrictive defect and decrease in diffusing capacity due to unilateral pleural and diaphragmatic disease, whose relationship to MTX therapy is uncertain, developed in one patient. MTX, when administered in high dose to young patients by the described protocol, causes no dose-related decrease in pulmonary function.

Original languageEnglish (US)
Pages (from-to)741-746
Number of pages6
JournalPediatrics
Volume63
Issue number5
StatePublished - 1979
Externally publishedYes

Fingerprint

Methotrexate
Lung
Pleural Diseases
Time and Motion Studies
Plethysmography
Spirometry
Interstitial Lung Diseases
Osteosarcoma
Therapeutics
Fibrosis
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Wall, M., Wohl, M. E. B., Jaffe, N., & Strieder, D. J. (1979). Lung function in adolescents receiving high-dose methotrexate. Pediatrics, 63(5), 741-746.

Lung function in adolescents receiving high-dose methotrexate. / Wall, Michael; Wohl, M. E B; Jaffe, N.; Strieder, D. J.

In: Pediatrics, Vol. 63, No. 5, 1979, p. 741-746.

Research output: Contribution to journalArticle

Wall, M, Wohl, MEB, Jaffe, N & Strieder, DJ 1979, 'Lung function in adolescents receiving high-dose methotrexate', Pediatrics, vol. 63, no. 5, pp. 741-746.
Wall M, Wohl MEB, Jaffe N, Strieder DJ. Lung function in adolescents receiving high-dose methotrexate. Pediatrics. 1979;63(5):741-746.
Wall, Michael ; Wohl, M. E B ; Jaffe, N. ; Strieder, D. J. / Lung function in adolescents receiving high-dose methotrexate. In: Pediatrics. 1979 ; Vol. 63, No. 5. pp. 741-746.
@article{5c9beaad6c3c4c39b90dde1eebbdff55,
title = "Lung function in adolescents receiving high-dose methotrexate",
abstract = "Methotrexate (MTX) has been implicated as a cause of interstitial pneumonitis and/or fibrosis, but the mechanism by which the drug causes these processes is not known. The purpose of this study was to determine whether patients receiving high-dose MTX developed a consistent decrease in pulmonary function, which would implicate a role for total dose of MTX received in the pathogenesis of the lung toxicity. Pulmonary function studies, including spirometry, plethysmography, and diffusing capacity at two levels of alveolar P(O)2, were performed in 38 adolescents treated for osteogenic sarcoma. The patients were divided into three groups including 12 patients (group 1) studied before and during therapy, 15 patients (group 2) studied during therapy, and 11 patients (group 3) studied after completion of treatment. While total dose received at the time of the study varied from 0 to 256 gm/sq m, pulmonary function showed no change, with one exception. A mild restrictive defect and decrease in diffusing capacity due to unilateral pleural and diaphragmatic disease, whose relationship to MTX therapy is uncertain, developed in one patient. MTX, when administered in high dose to young patients by the described protocol, causes no dose-related decrease in pulmonary function.",
author = "Michael Wall and Wohl, {M. E B} and N. Jaffe and Strieder, {D. J.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "741--746",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - Lung function in adolescents receiving high-dose methotrexate

AU - Wall, Michael

AU - Wohl, M. E B

AU - Jaffe, N.

AU - Strieder, D. J.

PY - 1979

Y1 - 1979

N2 - Methotrexate (MTX) has been implicated as a cause of interstitial pneumonitis and/or fibrosis, but the mechanism by which the drug causes these processes is not known. The purpose of this study was to determine whether patients receiving high-dose MTX developed a consistent decrease in pulmonary function, which would implicate a role for total dose of MTX received in the pathogenesis of the lung toxicity. Pulmonary function studies, including spirometry, plethysmography, and diffusing capacity at two levels of alveolar P(O)2, were performed in 38 adolescents treated for osteogenic sarcoma. The patients were divided into three groups including 12 patients (group 1) studied before and during therapy, 15 patients (group 2) studied during therapy, and 11 patients (group 3) studied after completion of treatment. While total dose received at the time of the study varied from 0 to 256 gm/sq m, pulmonary function showed no change, with one exception. A mild restrictive defect and decrease in diffusing capacity due to unilateral pleural and diaphragmatic disease, whose relationship to MTX therapy is uncertain, developed in one patient. MTX, when administered in high dose to young patients by the described protocol, causes no dose-related decrease in pulmonary function.

AB - Methotrexate (MTX) has been implicated as a cause of interstitial pneumonitis and/or fibrosis, but the mechanism by which the drug causes these processes is not known. The purpose of this study was to determine whether patients receiving high-dose MTX developed a consistent decrease in pulmonary function, which would implicate a role for total dose of MTX received in the pathogenesis of the lung toxicity. Pulmonary function studies, including spirometry, plethysmography, and diffusing capacity at two levels of alveolar P(O)2, were performed in 38 adolescents treated for osteogenic sarcoma. The patients were divided into three groups including 12 patients (group 1) studied before and during therapy, 15 patients (group 2) studied during therapy, and 11 patients (group 3) studied after completion of treatment. While total dose received at the time of the study varied from 0 to 256 gm/sq m, pulmonary function showed no change, with one exception. A mild restrictive defect and decrease in diffusing capacity due to unilateral pleural and diaphragmatic disease, whose relationship to MTX therapy is uncertain, developed in one patient. MTX, when administered in high dose to young patients by the described protocol, causes no dose-related decrease in pulmonary function.

UR - http://www.scopus.com/inward/record.url?scp=0018374070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018374070&partnerID=8YFLogxK

M3 - Article

C2 - 440894

AN - SCOPUS:0018374070

VL - 63

SP - 741

EP - 746

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -